86 related articles for article (PubMed ID: 19237273)
1. Tubers and tumors: rapamycin therapy for benign and malignant tumors.
Plas DR; Thomas G
Curr Opin Cell Biol; 2009 Apr; 21(2):230-6. PubMed ID: 19237273
[TBL] [Abstract][Full Text] [Related]
2. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
4. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
5. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
6. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H; Hidalgo M
Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin: an anti-cancer immunosuppressant?
Law BK
Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
[TBL] [Abstract][Full Text] [Related]
8. Optimal targeting of the mTORC1 kinase in human cancer.
Lane HA; Breuleux M
Curr Opin Cell Biol; 2009 Apr; 21(2):219-29. PubMed ID: 19233631
[TBL] [Abstract][Full Text] [Related]
9. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
10. An expanding role for mTOR in cancer.
Guertin DA; Sabatini DM
Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
[TBL] [Abstract][Full Text] [Related]
11. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
van Veelen W; Korsse SE; van de Laar L; Peppelenbosch MP
Oncogene; 2011 May; 30(20):2289-303. PubMed ID: 21258412
[TBL] [Abstract][Full Text] [Related]
12. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
Janus A; Robak T; Smolewski P
Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
[TBL] [Abstract][Full Text] [Related]
13. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].
Dos Santos C; Récher C; Demur C; Payrastre B
Bull Cancer; 2006 May; 93(5):445-7. PubMed ID: 16777621
[TBL] [Abstract][Full Text] [Related]
14. L-leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport.
Peyrollier K; Hajduch E; Blair AS; Hyde R; Hundal HS
Biochem J; 2000 Sep; 350 Pt 2(Pt 2):361-8. PubMed ID: 10947949
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.
Chen XG; Liu F; Song XF; Wang ZH; Dong ZQ; Hu ZQ; Lan RZ; Guan W; Zhou TG; Xu XM; Lei H; Ye ZQ; Peng EJ; Du LH; Zhuang QY
Mol Carcinog; 2010 Jun; 49(6):603-10. PubMed ID: 20512842
[TBL] [Abstract][Full Text] [Related]
18. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
Malaguti P; Vari S; Cognetti F; Fabi A
Anticancer Res; 2013 Jan; 33(1):21-8. PubMed ID: 23267124
[TBL] [Abstract][Full Text] [Related]
19. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Huang JJ; Lin TY
Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Tirado OM; Mateo-Lozano S; Notario V
Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
